

Drug Class Review Monograph – GPI Class 15 – Anthelmintics

Review Time Frame: 02/2016 – 04/2017

Previous Class Review: 05/2016

Background:

Anthelmintics are medications used for treatment of symptomatic disease caused by multicellular parasites called helminths. The mechanisms of action for many anthelmintic agents are not completely understood.

New treatment guideline recommendations:

- None identified

Newly approved drugs:

- None identified

Newly approved formulations:

- Approved 10/19/2016: Vermox (mebendazole) 500 mg chewable tablet; anticipated commercial availability unknown.

Newly approved generics:

- None identified

Discontinued drugs:

- None identified

FDA Safety Alerts/black box warnings:

- None identified

Pipeline alerts:

Agents pending FDA approval include:

- None identified

References:

1. Weller PF. Anthelmintic therapies. Leder K (Ed), UpToDate. Waltham MA. Accessed May 2017.
2. Food and Drug Administration. WWW.FDA.GOV. Accessed May 2017.
3. Envolve Pharmacy Solutions internal pipeline database. Accessed May 2017.